Rosiglitazone belongs to a class of drugs known as peroxisome proliferator-actiated receptor (PPAR) agonists.
罗格列酮属于称为过氧化物酶体活化受体（PPAR）促效剂一类药物。
The results showed that the peroxisome mainly exists in the R-cell of hepatopancreas and the labyrinth epithelium of antennary gland.
过氧化物酶体主要存在于肝胰腺细胞和触角腺的迷路上皮细胞中。
Studies of the role of the peroxisome proliferators-activated receptor plays in lipotoxic cardiomyopathy will provide new strategies to prevent and cure lipotoxic cardiomyopathy.
研究过氧化物酶体增殖剂活化受体在脂毒性心肌病中的作用，可以为预防和治疗脂毒性心肌病提供新思路。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
应用推荐